OncoMatch/Clinical Trials/NCT06229340
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Is NCT06229340 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Leflunomide and The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab for ras mutation.
Treatment: Leflunomide · The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab — There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Melanoma
Tumor Agnostic
Biomarker criteria
Required: HRAS mutation
Required: KRAS mutation
Required: NRAS mutation
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/μL); lymphocyte count ≥ 0.5 x 10^9/L (500/μL); platelet count ≥ 100 x 10^9/L (100,000/μL) without transfusion; hemoglobin ≥ 90 g/L without transfusion
Kidney function
Creatinine clearance ≥ 40 mL/min
Liver function
Serum bilirubin ≤ 1.5 x HGH (≤ 3 x IUH for Gilbert's disease or liver metastases); AST, ALT, and alkaline phosphate ≤ 2.5 x HGN
Cardiac function
left ventricular ejection fraction (LVEF) ≥ 45%
Appropriate hematologic and liver function: ANC ≥ 1.5 x 10^9/L (1500/μL); lymphocyte count ≥ 0.5 x 10^9/L (500/μL); platelet count ≥ 100 x 10^9/L (100,000/μL) without transfusion; hemoglobin ≥ 90 g/L without transfusion. Creatinine clearance ≥ 40 mL/min. Serum albumin ≥ 25 g/L (2.5 g/dL). Serum bilirubin ≤ 1.5 x HGH, with the following exception: Patients with known Gilbert's disease or liver metastases: serum bilirubin level ≤ 3 x IUH. AST, ALT, and alkaline phosphate ≤ 2.5 x HGN; Exclusion: Impaired renal and hepatic function; - left ventricular ejection fraction (LVEF) < 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06229340 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify